After-hours trading on Wednesday saw a big recovery in Jaguar Health, Inc. (NASDAQ: JAGX) shares, which rose 8.33% to $3.01. The shares ended the trading day at $2.78, somewhat offsetting the company’s previous 14.06% regular-session drop. The recovery followed a virtual presentation at the Emerging Growth Conference by Lisa Conte, the founder and CEO of Jaguar Health, outlining the company’s recent accomplishments and future objectives.
Advancing Canalevia-CA1 in Veterinary Medicine
Recently, a field research was started by Jaguar Health’s Jaguar Animal Health subsidiary for Canalevia-CA1, an FDA-conditionally authorized medicine for canine chemotherapy-induced diarrhea (CID). This prospective, randomized, open-label clinical research, which involves dogs receiving chemotherapy across the United States, has seen the establishment of the company’s first study site. The research compares the results of the treatment and control groups in order to gather empirical data in favor of complete FDA clearance.
Enhanced Indications and Strategic Objectives
Securing complete FDA clearance for the CID indication and expanding its usage to treat general, non-infectious diarrhea in dogs are the two primary goals Jaguar Health is pursuing with Canalevia-CA1 (crofelemer delayed-release tablets). Discussions are underway with potential partners to support the development and global commercialization of crofelemer for this broader indication.
This strategic expansion reflects the company’s recognition of a significant unmet need in veterinary medicine. Jaguar Health estimates approximately six million annual cases of acute and chronic canine diarrhea are seen by U.S. veterinarians, marking a considerable market opportunity.
Regulatory Progress and Development Focus
Jaguar Health has opened a new Investigational New Animal Drug (INAD) filing with the FDA’s Center for Veterinary Medicine to investigate the possibility of using crofelemer to treat dogs’ general, non-infectious diarrhea in order to assist these efforts. As a major driver of its continuous business growth activities, the firm has determined that establishing a strategic alliance for this program is a top goal for 2025.
